Abstract:Purpose(:) To evaluate the pharmacokinetic parameters of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in diagnosing and staging liver fibrosis in rabbits.Materials and Methods: DCE-MRI with gadodiamide (Gd-DTPA-BMA) was performed on a 3.0 Tesla, 60cm bore MR scanner for rabbits with CCl4-induced liver fibrosis, and an untreated control group. Fibrosis was staged according to the METAVIR system: control (F0; n=13), nonadvanced fibrosis (F1-2; n=15), and advanced fibrosis (F3-4; n=12). The DCE-MRI parameters K-trans, k(ep), V-e, and v(p) were measured with a dual-input extended Tofts model. Receiver operating characteristic analyses were performed to assess the diagnostic performance of K-trans, V-e, and v(p) in staging liver fibrosis.Results: Both K-trans and V-e decreased with increasing fibrosis stage. K-trans of the control group was significantly different from that of the overall fibrosis group, nonadvanced group, and advanced group (P < 0.001 for all). Significant differences were found between V-e of the control group and that of the overall fibrosis and advanced groups (P=0.019 and P=0.009, respectively). For K-trans, the areas under the receiver operating characteristic curve (AUROCs) for discriminating the control group from the overall fibrosis and advanced fibrosis groups were 0.909 (95% confidence interval [CI], 0.809-1.000), and 0.936 (95% CI, 0.847-1.000), respectively. For discriminating between the control and nonadvanced fibrosis groups, the AUROC of K-trans was 0.887 (95% CI, 0.762-1.000). The AUROCs of K-trans were higher than those of V-e and v(p) for discriminating between the control and overall fibrosis groups, the control and nonadvanced fibrosis groups, and the control and advanced fibrosis groups. Pharmacokinetic parameters were negatively correlated with fibrosis stage (K-trans, rho=-0.668, P < 0.001; V-e, rho=-0.438, P=0.005; v(p), rho=-0.360, P=0.023).Conclusion: Among pharmacokinetic parameters of DCE-MRI in our study, K-trans was an excellent predictor for differentiating fibrotic livers from normal livers, and differentiating normal livers from nonadvanced or advanced fibrosis livers.

State-of-the-art imaging of liver fibrosis and cirrhosis: A comprehensive review of current applications and future perspectives

[Functional MR Study of Hepatic Fibrosis].

Recent advances in molecular magnetic resonance imaging of liver fibrosis.

T1 Mapping, T2 Mapping and MR Elastography of the Liver for Detection and Staging of Liver Fibrosis.

Current Imaging Techniques for Noninvasive Staging of Hepatic Fibrosis

Advancements of non‐invasive imaging technologies for the diagnosis and staging of liver fibrosis: Present and future

Interpretation, Reporting, and Clinical Applications of Liver MR Elastography

Noninvasive staging of liver fibrosis: review of current quantitative CT and MRI-based techniques

Progress and Prospects of Elastography Techniques in the evaluation of fibrosis in chronic liver disease

Multidetector Computed Tomography for Retrospective, Noninvasive Staging of Liver Fibrosis

Noninvasive diagnosis of liver cirrhosis: qualitative and quantitative imaging biomarkers

Computed tomography findings in liver fibrosis and cirrhosis

Assessment of Liver Fibrosis Using Pharmacokinetic Parameters of Dynamic Contrast-Enhanced Magnetic Resonance Imaging.

Assessment of Chronic Hepatitis and Fibrosis: Comparison of MR Elastography and Diffusion-Weighted Imaging.

Noninvasive Assessment of Liver Fibrosis: Current and Future Clinical and Molecular Perspectives

Accuracy Of Mr Elastography And Anatomic Mr Imaging Features In The Diagnosis Of Severe Hepatic Fibrosis And Cirrhosis

Liver MR Elastography Technique and Image Interpretation: Pearls and Pitfalls

Imaging-based non-invasive liver disease assessment for staging liver fibrosis in chronic liver disease: A systematic review supporting the AASLD Practice Guideline

Imaging-Based Staging of Hepatic Fibrosis in Patients with Hepatitis B: A Dynamic Radiomics Model Based on Gd-EOB-DTPA-Enhanced MRI

Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future

Liver Magnetic Resonance Elastography: Focus on Methodology, Technique, and Feasibility